Since 2007, the I-MOVE network measures influenza vaccine effectiveness during the influenza season. The network makes its data available to the health authorities as soon as possible after the start of the seasonal epidemic or pandemic. This point is crucial to deploy an appropriate response, and in particular, to: 

  • Decide on recommendations to be communicated for vaccine use,
  • Target complementary or alternative measures (e.g. antivirals) for population subgroups in which the vaccine is less effective,
  • Accurately estimate the impact of current vaccination strategies on the disease so as to support vaccination campaigns,
  • Initiate further research on seasonal and pandemic vaccines (to improve composition, decide on the use of adjuvants or the need for booster doses),
  • Anticipate when the vaccine will be out of stock (especially during a pandemic). 

The I-MOVE network was initiated with funding from Member States and the European Centre for Disease Prevention and Control (ECDC) and has been coordinated by Epiconcept ever since. From 2015 to 2018 the European Commission's Horizon 2020 programme contributed to the funding of the network and allowed to set up a hospital network to measure vaccine effectiveness at hospital level. The World Health Organization Regional office for Europe is contributing to the financing of a study site in Romania. 

For the 2018/2019 season, Epiconcept is funding the activities of the I-Move hospital network.

For more information: 

https://sites.google.com/site/epiflu/about-i-move/project-background

http://www.i-moveplus.eu/

Project funded by:

ecdc
Le_programme_H2020_276193.148